• MiniMed reported results from a randomized crossover clinical trial, published today, showing similar glucose-control outcomes when its MiniMed 780G automated insulin delivery system used either its Simplera Sync sensor or Abbott’s Instinct sensor.
• The findings support the view that the system’s automated insulin-dosing algorithm is the main driver of performance, reducing dependence on any single sensor option.
• No severe safety events were reported during the study, including no diabetic ketoacidosis or severe hypoglycemia.
• The clinical results follow earlier real-world analyses, including data previously presented in March, that showed users maintained comparable outcomes when switching sensors within the 780G ecosystem.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiniMed Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605210833PR_NEWS_USPR_____LA64827) on May 21, 2026, and is solely responsible for the information contained therein.